Nanotheranostic Approach for Targeting Tauopathies in Alzheimer's Disease: Mechanistic Insight and Recent Advances
- 1 February 2026
- journal article
- Published by Bentham Science Publishers Ltd. in Drug Delivery Letters
- Vol. 16 (1) , 23-41
Abstract
The most prevalent type of dementia, Alzheimer's disease (AD), is typified by the presence of intracellular tau protein neurofibrillary tangles and extracellular amyloid plaques. There are currently about 50 million people who have dementia, and by 2030, that number is predicted to rise to 75 million, placing a significant financial strain on the nation's healthcare system. Novel disease-modifying treatments are desperately needed to combat this illness, given the consequences on patients' quality of life and the mounting financial strain. There are currently no disease- modifying medications available; instead, the majority of available therapies are symptomatic ones such as cholinesterase inhibitors and N-methyl-D-aspartate receptor blockers. The primary focus of therapeutic research against AD has shifted to tau-targeting strategies following multiple unsuccessful attempts to create medications against amyloidopathy. This article first provides an introduction to tauopathy in AD before summarizing current research on the creation of tau-oriented multi-target directed ligands and small compounds as therapies that target tau alteration, aggregation, and degradation. The overall goal of this work is to present a thorough and critical review of small compounds that are being investigated as potential treatment candidates for AD tauopathy.Keywords
This publication has 194 references indexed in Scilit:
- Role of uric acid in neurodegenerative diseases, focusing on Alzheimer and Parkinson disease: A new perspectiveNeuropsychopharmacology Reports, 2024
- Conformational Dynamics of Intracellular Tau Protein Revealed by CD and SAXS2016
- Global Conformation of Tau Protein Mapped by Raman Spectroscopy2016
- Intranasal Piperine-Loaded Chitosan Nanoparticles as Brain-Targeted Therapy in Alzheimer's Disease: Optimization, Biological Efficacy, and Potential ToxicityJournal of Pharmaceutical Sciences, 2015
- Gold‐Nanoparticle‐Based Multifunctional Amyloid‐β Inhibitor against Alzheimer’s DiseaseChemistry – A European Journal, 2014
- Negatively Charged Gold Nanoparticles Inhibit Alzheimer's Amyloid‐β Fibrillization, Induce Fibril Dissociation, and Mitigate NeurotoxicitySmall, 2012
- A Highly Sensitive Gold‐Nanoparticle‐Based Assay for Acetylcholinesterase in Cerebrospinal Fluid of Transgenic Mice with Alzheimer's DiseaseAdvanced Healthcare Materials, 2011
- Different Hydration Changes Accompanying Copper and Zinc Binding to Amyloid β‐Peptide: Water Contribution to Metal BindingChemBioChem, 2008
- How Metal Ions Affect Amyloid Formation: Cu2+‐ and Zn2+‐Sensitive PeptidesChemBioChem, 2008
- Proapoptotic Effects of Tau Cleavage Product Generated by Caspase-3Neurobiology of Disease, 2001